Is 2022 the endemic year?

Context and Market Sentiment:

• The episode addresses the transition from the Omicron surge to potential endemicity in 2022, noting a market pivot from virus fears to inflation concerns driven by pandemic-era stimulus.
• Goldman Sachs Research frames the central question as whether Omicron's characteristics signal a manageable endemic phase or if new, unpredictable variants remain a significant risk.

Omicron Transmissibility and Biological Mechanisms (Jeffrey Shaman):

• Omicron replicates in human lung tissue faster than Delta, leading to higher viral titers and shorter latency periods (time from infection to contagiousness).
• The variant achieves high viral loads earlier, increasing respiratory droplet shedding and allowing it to displace Delta, which had lower transmissibility than Alpha and ancestral variants.
• Transmissibility is further amplified by a large pool of individuals previously protected by Delta immunity but susceptible to Omicron's specific mutations.
• Omicron primarily infects the upper respiratory tract (causing runny noses) rather than the lower respiratory tract, which typically causes severe oxygen exchange issues and cytokine storms.

Evolutionary Theory and Future Severity:

• Shaman rejects the evolutionary theory that pathogens must inevitably evolve to be less virulent; there is no selective pressure for SARS-CoV-2 to become milder because transmission occurs largely before hosts are symptomatic or critical.
• Unlike influenza, which has reached an evolutionary optimum, SARS-CoV-2 is still exploring its transmissible capabilities with new lineages emerging unpredictably.
• The virus does not threaten to "kill off" the host population, meaning there is no evolutionary incentive to reduce severity to ensure host survival.
• Future variants are not guaranteed to follow Omicron's pattern; selective pressure will favor variants that best evade existing immunity, potentially emerging from anywhere on the phylogenetic tree.

Public Health Assessment and Severity Nuance (Eric Topol):

• Topol argues that characterizing Omicron as "mild" is a misperception; despite a lower severity rate per case, the sheer volume of infections results in high absolute numbers of severe cases and hospitalizations.
• The unpredictability of Omicron's emergence was a major curveball; virologists predicted a Delta sub-lineage, but Omicron possessed numerous mutations across the entire virus, not just the spike protein.
• Without global vaccine equity and boosters, the virus could evolve into a variant with true immune escape that bypasses current vaccination coverage, representing a worse-case scenario.
• Topol remains cautiously optimistic that the population may be entering an endemic phase, though he warns against assuming Omicron is the final evolutionary stop.

Immunity and Vaccine Efficacy:

• Experts express "extraordinary luck" that prior infection and two-dose vaccines retained efficacy against Omicron's mutations, with antibodies preventing hospitalization at 50% and rising to >90% with boosters.
• Adaptive immunity (memory B cells and T cells) provides robust protection against severe outcomes even when antibodies do not prevent infection or symptoms entirely.
• Shaman posits that the "immunity wall" built through vaccination and natural exposure contributes to Omicron's observed milder impact, though the virus itself may not be intrinsically evolving toward mildness.
• The immune system is capable of ramping up T-cell responses and antibody production to clear variants, preventing the severe pathology seen in the early pandemic.

Therapeutics and Future Tools:

• Pfizer's Paxlovid is identified as a "just-in-time breakthrough" and a game changer for preventing severe disease across all variants.
• Unlike monoclonal antibodies which fail against immune-evasive variants, Paxlovid targets the Main Protease (Mpro), a stable viral component with only one mutation recorded in two years.
• Paxlovid reduces viral load tenfold and demonstrates ~90% efficacy in preventing hospitalization and death, with safety profiles comparable to placebo.
• The drug acts as an "immune-independent" treatment, inactivating the virus directly at its replication choke point without relying on the host's immune response.

Path to Endemicity and Timeline:

• Both experts caution that declaring the virus "endemic" based on a few data points is premature; establishing a pattern requires long-term observation similar to climate data analysis.
• Endemicity is projected to arrive as population immunity confers protection against severe outcomes, allowing the virus to behave more like seasonal flu (ORC43), though multiple outbreaks per year are possible due to high transmissibility.
• Topol notes that achieving endemicity relies on two unfulfilled routes: 90% population vaccination (currently at 62% in the US) or the development of a pan-coronavirus vaccine and widespread access to antivirals.
• The transition to a manageable endemic state is tentatively expected within 2022 but remains contingent on the absence of a new, highly disruptive variant in 2023 or 2024.
• The prevailing view is that while disruption may subside, the virus will likely persist, requiring continuous caution and management of healthcare capacity during surges.